Epigenetic Silencing of PRSS3 Provides Growth and Metastasis Advantage for Human Hepatocellular Carcinoma

Overview

Journal J Mol Med (Berl)

Specialty General Medicine

Date 2017 Aug 28

PMID 28844099

Citations 11

Authors

Bonan Lin

Xiaomeng Zhou

Shuye Lin

Xiaoyue Wang

Meiying Zhang

Baoping Cao

Yan Dong

Shuai Yang

Ji Ming Wang

Mingzhou Guo

Jiaqiang Huang

Affiliations

Soon will be listed here.

Abstract

Key Messages: • PRSS3 is downregulated by intragenic hypermethylation in HCC. • Epigenetic silencing of PRSS3 facilitates growth, migration, and invasion of HCC. • PRSS3 intragenic methylation has implication in diagnosis of HCC.

Citing Articles

Polydopamine Nanoparticle-Based Combined Chemotherapy and Photothermal Therapy for the Treatment of Liver Cancer.

Emanet M, Lefevre M, Ceccarelli M, Battaglini M, Carmignani A, Schiavone F ACS Appl Mater Interfaces. 2024; 16(31):40695-40713.

PMID: 39058979 PMC: 11310915. DOI: 10.1021/acsami.4c08491.

Shear Stress Drives the Cleavage Activation of Protease-Activated Receptor 2 by PRSS3/Mesotrypsin to Promote Invasion and Metastasis of Circulating Lung Cancer Cells.

Zhou M, Li K, Luo K Adv Sci (Weinh). 2023; 10(25):e2301059.

PMID: 37395651 PMC: 10477893. DOI: 10.1002/advs.202301059.

UHRF1/DNMT1-MZF1 axis-modulated intragenic site-specific CpGI methylation confers divergent expression and opposing functions of isoforms in lung cancer.

Lin S, Xu H, Qin L, Pang M, Wang Z, Gu M Acta Pharm Sin B. 2023; 13(5):2086-2106.

PMID: 37250150 PMC: 10213989. DOI: 10.1016/j.apsb.2023.02.015.

Serine Protease 3 Promotes Progression of Diffuse Large B-Cell Lymphoma and Serves as a Novel Prognostic Predictor.

Zheng L, Wang X, Zheng W, Huang H Dis Markers. 2023; 2022:1254790.

PMID: 36618965 PMC: 9822761. DOI: 10.1155/2022/1254790.

CpG Site-Specific Methylation-Modulated Divergent Expression of Transcript Variants Facilitates Nongenetic Intratumor Heterogeneity in Human Hepatocellular Carcinoma.

Lin S, Xu H, Pang M, Zhou X, Pan Y, Zhang L Front Oncol. 2022; 12:831268.

PMID: 35480112 PMC: 9035874. DOI: 10.3389/fonc.2022.831268.

References

Lin S, Lin B, Wang X, Pan Y, Xu Q, He J . Silencing of ATP4B of ATPase H/K Transporting Beta Subunit by Intragenic Epigenetic Alteration in Human Gastric Cancer Cells. Oncol Res. 2017; 25(3):317-329. PMC: 7840950. DOI: 10.3727/096504016X14734735156265. View

Frenette C, Gish R . Hepatocellular carcinoma: molecular and genomic guideline for the clinician. Clin Liver Dis. 2011; 15(2):307-21, vii-x. DOI: 10.1016/j.cld.2011.03.010. View

Nyaruhucha C, Kito M, Fukuoka S . Identification and expression of the cDNA-encoding human mesotrypsin(ogen), an isoform of trypsin with inhibitor resistance. J Biol Chem. 1997; 272(16):10573-8. DOI: 10.1074/jbc.272.16.10573. View

Jjingo D, Conley A, Yi S, Lunyak V, Jordan I . On the presence and role of human gene-body DNA methylation. Oncotarget. 2012; 3(4):462-74. PMC: 3380580. DOI: 10.18632/oncotarget.497. View

Wojtukiewicz M, Hempel D, Sierko E, Tucker S, Honn K . Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis. Cancer Metastasis Rev. 2015; 34(4):775-96. PMC: 4661218. DOI: 10.1007/s10555-015-9599-4. View

Marsit C, Karagas M, Schned A, Kelsey K . Carcinogen exposure and epigenetic silencing in bladder cancer. Ann N Y Acad Sci. 2006; 1076:810-21. DOI: 10.1196/annals.1371.031. View

Diederichs S, Bulk E, Steffen B, Ji P, Tickenbrock L, Lang K . S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res. 2004; 64(16):5564-9. DOI: 10.1158/0008-5472.CAN-04-2004. View

Hockla A, Radisky D, Radisky E . Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res Treat. 2009; 124(1):27-38. PMC: 2929293. DOI: 10.1007/s10549-009-0699-0. View

Su S, Li Y, Luo Y, Sheng Y, Su Y, Padia R . Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene. 2009; 28(34):3047-57. PMC: 2733915. DOI: 10.1038/onc.2009.163. View

10.

Marsit C, Okpukpara C, Danaee H, Kelsey K . Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer. Mol Carcinog. 2005; 44(2):146-50. DOI: 10.1002/mc.20125. View

11.

Wiegand U, Corbach S, Minn A, Kang J, Muller-Hill B . Cloning of the cDNA encoding human brain trypsinogen and characterization of its product. Gene. 1993; 136(1-2):167-75. DOI: 10.1016/0378-1119(93)90460-k. View

12.

Wei J, Greer B, Westermann F, Steinberg S, Son C, Chen Q . Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 2004; 64(19):6883-91. PMC: 1298184. DOI: 10.1158/0008-5472.CAN-04-0695. View

13.

Golubnitschaja O, Yeghiazaryan K, Stricker H, Trog D, Schild H, Berliner L . Patients with hepatic breast cancer metastases demonstrate highly specific profiles of matrix metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared to other primary and secondary liver tumours. BMC Cancer. 2016; 16:357. PMC: 4898377. DOI: 10.1186/s12885-016-2382-2. View

14.

Rowen L, Williams E, Glusman G, Linardopoulou E, Friedman C, Ahearn M . Interchromosomal segmental duplications explain the unusual structure of PRSS3, the gene for an inhibitor-resistant trypsinogen. Mol Biol Evol. 2005; 22(8):1712-20. DOI: 10.1093/molbev/msi166. View

15.

Soreide K, Janssen E, Korner H, Baak J . Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. J Pathol. 2006; 209(2):147-56. DOI: 10.1002/path.1999. View

16.

Radisky E . PRSS3/mesotrypsin in prostate cancer progression: implications for translational medicine. Asian J Androl. 2013; 15(4):439-40. PMC: 3739227. DOI: 10.1038/aja.2013.14. View

17.

Hockla A, Miller E, Salameh M, Copland J, Radisky D, Radisky E . PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer. Mol Cancer Res. 2012; 10(12):1555-66. PMC: 3531873. DOI: 10.1158/1541-7786.MCR-12-0314. View

18.

Sahin-Toth M . Human mesotrypsin defies natural trypsin inhibitors: from passive resistance to active destruction. Protein Pept Lett. 2005; 12(5):457-64. PMC: 1488880. DOI: 10.2174/0929866054395356. View

19.

Maunakea A, Nagarajan R, Bilenky M, Ballinger T, DSouza C, Fouse S . Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010; 466(7303):253-7. PMC: 3998662. DOI: 10.1038/nature09165. View

20.

Wang Y, Jadhav R, Liu J, Wilson D, Chen Y, Thompson I . Roles of Distal and Genic Methylation in the Development of Prostate Tumorigenesis Revealed by Genome-wide DNA Methylation Analysis. Sci Rep. 2016; 6:22051. PMC: 4770430. DOI: 10.1038/srep22051. View